© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Hematology
EQUATE Study Shows Early Response Rates in Severe Acute GVHD
August 11, 2020
ByHannah SlaterThe study is evaluating itolizumab in patients with severe acute graft-versus-host disease as a first-line treatment concomitant with standard of care.
Phase 3 REACH3 Study Meets Primary Endpoint of Superior Overall Response Rate
July 23, 2020
ByHannah SlaterThe study is evaluating ruxolitinib in patients with refractory or steroid-dependent chronic graft-versus-host disease compared to best available therapy.
Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN Trial
July 16, 2020
ByConstantine Si Lun Tam, MD, MBBS, FRACP, FRCPAThe trial evaluated zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.